BEAM THERAPEUTICS INC(NASDAQ:BEAM) stock News

BEAM Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: Benzinga

Is Beam Therapeutics Gaining or Losing Market Support?

7 days ago - By: Benzinga - Mentions: ILMN VRTX LLY NVO ...

My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years

a month ago - By: Zacks Investment Research - Mentions: VRTX NTLA CRSP

Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy?

a month ago - By: Zacks Investment Research - Mentions: VRTX CRSP

CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now?

a month ago - By: Beam Therapeutics

Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences

a month ago - By: Beam Therapeutics

Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences

a month ago - By: Zacks Investment Research - Mentions: VRTX NTLA CRSP

CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock

a month ago - By: Beam Therapeutics

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

a month ago - By: Beam Therapeutics

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

a month ago - By: Zacks Investment Research - Mentions: VRTX NTLA CRSP

Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings?

2 months ago - By: Zacks Investment Research - Mentions: CRMD ARVN IMCR

BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark

2 months ago - By: Zacks Investment Research - Mentions: CVAC

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates

2 months ago - By: Beam Therapeutics

Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)

2 months ago - By: Beam Therapeutics

Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)

2 months ago - By: Zacks Investment Research - Mentions: CRSP

Will Beam Therapeutics Inc. (BEAM) Report Negative Q2 Earnings? What You Should Know

3 months ago - By: Yahoo Finance

H.C. Wainwright Reiterates a Buy Rating on Beam Therapeutics (BEAM) With an $80 PT

3 months ago - By: Yahoo Finance - Mentions: CERT INSP

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

3 months ago - By: The Motley Fool - Mentions: TMDX PODD OPCH LFMD ...

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

3 months ago - By: Investor's Business Daily - Mentions: GILD CRSP SRPT LEGN ...

The FDA Shake-Up Continues, And Could Impact Genetic Medicines

3 months ago - By: Investor's Business Daily - Mentions: LLY VERV NTLA EDIT ...

Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover

3 months ago - By: Yahoo Finance - Mentions: LLY VERV KHC NTLA

Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B

3 months ago - By: Beam Therapeutics

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

3 months ago - By: Beam Therapeutics

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

4 months ago - By: Zacks Investment Research - Mentions: BMY

Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue?

4 months ago - By: Yahoo Finance - Mentions: DLTR NTLA SMCI NVDA

Biotech funding plummets as Trump policies unnerve investors: Jefferies

4 months ago - By: Beam Therapeutics

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

4 months ago - By: Yahoo Finance - Mentions: REVB ESLT CTKB KROS ...

Revelation Biosciences, Inc. (REVB) Raises $4M in Public Offering

4 months ago - By: Yahoo Finance - Mentions: VREX CTKB KROS CADL ...

Varex Imaging Corporation (VREX) Downgraded by S&P as Regulatory Outlook Remains Cloudy

4 months ago - By: Beam Therapeutics

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

4 months ago - By: Beam Therapeutics

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

4 months ago - By: Zacks Investment Research - Mentions: ILMN QURE NTLA CRSP ...

3 Top Genomics Stocks to Add to Your Portfolio in 2025

4 months ago - By: Beam Therapeutics

BEAM THERAPEUTICS INC (BEAM) Stock News

BEAM Latest News, Press Relases and Analysis

Is Beam Therapeutics Gaining or Losing Market Support?

My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years

Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy?

CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now?

Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences

Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences

CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings?

BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates

Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)

Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)

Will Beam Therapeutics Inc. (BEAM) Report Negative Q2 Earnings? What You Should Know

H.C. Wainwright Reiterates a Buy Rating on Beam Therapeutics (BEAM) With an $80 PT

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

The FDA Shake-Up Continues, And Could Impact Genetic Medicines

Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover

Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue?

Biotech funding plummets as Trump policies unnerve investors: Jefferies

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

Revelation Biosciences, Inc. (REVB) Raises $4M in Public Offering

Varex Imaging Corporation (VREX) Downgraded by S&P as Regulatory Outlook Remains Cloudy

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

3 Top Genomics Stocks to Add to Your Portfolio in 2025

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress